^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LXF821

    i
    Other names: LXF821, CART-EGFRvIII T cells, LXF-821, LXF 821
    Associations
    News
    Trials
    Company:
    Novartis, University of Pennsylvania
    Drug class:
    EGFRvIII-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News
    Trials